Journal of atherosclerosis and thrombosis · 2014
Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why?
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Bum Joon, Hong Keun-Sik, Cho Yong-Jin, Lee Ju-Hun, Koo Ja-seong, Park Jong-Moo, Kang Dong-Wha, Kim Jong S, Lee Seung-Hoon, Kwon Sun U, TOSS-2 investigators
Аннотация
AIM: The prognoses of symptomatic and asymptomatic intracranial atherosclerotic stenosis(ICAS) differ. Understanding the underlying pathomechanisms and predictors of progression or regression may help to clarify the differences. We herein attempted to compare the course and predictors of symptomatic ICAS to those of coexisting asymptomatic ICAS.
METHODS: This was a post-hoc analysis of the 'Trials of Cilostazol in Symptomatic intracranial arterial stenosis-2(TOSS-2)' study, which recruited patients with acute symptomatic ICAS receiving intensive medical treatment. Changes in the status of ICAS were classified as being indicative of regression, progression or no changes. Univariate and multivariate ordinal regression analyses were performed to identify predictors of symptomatic and asymptomatic ICAS based on clinical, laboratory and radiologic data.
RESULTS: Of the 409 patients, symptomatic ICAS demonstrated regression in 110(27%) cases and progression in 52(13%) cases. Among these patients, 250(61.1%) had asymptomatic ICAS, which regressed in 38(15%) cases and progressed in 16(6%) cases. Severe baseline stenosis, a high high-density lipoprotein(HDL) cholesterol level and the use of cilostazol were found to be independently associated with a favorable course of symptomatic ICAS(p＜0.001, p=0.005 and p=0.038, respectively). Regarding asymptomatic ICAS, severe stenosis, the use of angiotensin receptor antagonists and a low fasting glucose level were associated with a favorable course(p＜0.001, p=0.011 and p=0.007, respectively).
CONCLUSIONS: Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ. In this study, changes in the status of symptomatic ICAS were associated with the level of HDL cholesterol, which is known to affect the regression of atherosclerosis and vascular remodeling.
METHODS: This was a post-hoc analysis of the 'Trials of Cilostazol in Symptomatic intracranial arterial stenosis-2(TOSS-2)' study, which recruited patients with acute symptomatic ICAS receiving intensive medical treatment. Changes in the status of ICAS were classified as being indicative of regression, progression or no changes. Univariate and multivariate ordinal regression analyses were performed to identify predictors of symptomatic and asymptomatic ICAS based on clinical, laboratory and radiologic data.
RESULTS: Of the 409 patients, symptomatic ICAS demonstrated regression in 110(27%) cases and progression in 52(13%) cases. Among these patients, 250(61.1%) had asymptomatic ICAS, which regressed in 38(15%) cases and progressed in 16(6%) cases. Severe baseline stenosis, a high high-density lipoprotein(HDL) cholesterol level and the use of cilostazol were found to be independently associated with a favorable course of symptomatic ICAS(p＜0.001, p=0.005 and p=0.038, respectively). Regarding asymptomatic ICAS, severe stenosis, the use of angiotensin receptor antagonists and a low fasting glucose level were associated with a favorable course(p＜0.001, p=0.011 and p=0.007, respectively).
CONCLUSIONS: Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ. In this study, changes in the status of symptomatic ICAS were associated with the level of HDL cholesterol, which is known to affect the regression of atherosclerosis and vascular remodeling.